Scientific Reference

Ipamorelin

Evidence profile: Human Phase 2 evidence

Ipamorelin is a selective growth hormone releasing peptide (GHRP) that stimulates endogenous growth hormone (GH) secretion via activation of ghrelin (GHS-R1a) receptors in the pituitary. It is characterized by a highly selective profile, producing GH release without significant stimulation of cortisol or prolactin. This selectivity distinguishes it from earlier GHRPs, making it a preferred compound in research focused on body composition, recovery, sleep, and anti-aging. Its ability to preserve physiological GH pulsatility while minimizing off-target endocrine effects has positioned it as a core peptide in GH optimization protocols.

Published Research

  • Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

    Beck DE et al. · International journal of colorectal disease · 2014 · Clinical

    PMID 25331030 — View on PubMed
  • Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

    Gobburu JV et al. · Pharmaceutical research · 1999 · Clinical

    PMID 10496658 — View on PubMed